Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

TotalEnergies sees income drop on weaker gas prices

(Sharecast News) - French energy major TotalEnergies reported a slide in quarterly income on Friday, after gas prices softened. Adjusted earnings before interest, tax, depreciation and amortisation fell 19% at $11.5bn, while adjusted net income fell 22% in the three months to March end, to $5.1bn.

That was, however, better than the $5bn expected by analysts, after resilient oil trading helped offset the weaker gas market.

Integrated liquified natural gas (LNG) posted a 41% slump in adjusted net operating income, to $1.2bn, but exploration and production posted a far smaller 4% decline, to $2.6bn,

Patrick Pouyanne, chief executive, said the first quarter had seen "sustained oil prices and refining margins but softening gas prices".

He continued: "TotalEnergies demonstrates once again this quarter the relevance of its balance transition strategy that is anchored on two pillars, hydrocarbons and power, delivering strong results and an attractive shareholder return."

Looking ahead to the current quarter, TotalEnergies noted that Brent prices were "strong", supported by geopolitical tensions and the decision by Opec+ to maintain production quotas.

European gas prices, meanwhile, were trading within a range of $8 and $10/mbtu at the beginning of the second quarter.

"Given the evolution of oil and gas prices in recent months, and the lag effect on price formulas, TotalEnergies anticipates that its average LNG selling price should between $9 and $10/mbtu," it added.

Share this article

Related Sharecast Articles

Sirius Real Estate ups dividend as profits jump 32%
(Sharecast News) - Profits at business and industrial parks developer Sirius Real Estate surged by nearly a third in the year ended 31 March, helping the company to increase dividends for the tenth straight year.
GSK to appeal Delaware ruling on jury trials in Zantac cancer cases
(Sharecast News) - Pharma giant GSK said it would be appealing against a US court decision allowing jury trials in cases brought by cancer sufferers claiming its heartburn drug caused their condition.
AstraZeneca's lung cancer treatment recommended for approval in EU
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
China manufacturing PMI ticks up more than expected - Caixin
(Sharecast News) - Activity in China's manufacturing sector grew in May at the fastest rate in two years, according to data released on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.